Recent advances in the management of venous disease have focused largely on patients with superficial venous reflux, particularly with the use of endothermal technologies to ablate refluxing superficial veins. 1 Although the long-term effectiveness of these endovenous interventions remains unproven, laser, radiofrequency and foam treatments can be performed in an office-based setting and excellent early outcomes have been reported. 2 However, duplex studies have shown that reflux (or less commonly, occlusion) of deep veins is seen in around 40% of patients with chronic venous insufficiency and may be significant in 10-15%. The treatment of superficial reflux in patients with concomitant deep and superficial disease has been shown to be effective and may even result in correction of deep venous reflux in some patients. Nevertheless, most clinicians with an interest in phlebology will have managed these challenging patients with severe symptoms and deep venous disease.
Current treatment options for chronic deep venous insufficiency are limited. Conservative measures including leg elevation and compression hosiery may improve symptoms and prevent ulceration, but patient compliance is often poor. 2 Moreover, compression may exacerbate symptoms in patients with deep venous occlusion, reliant on superficial venous channels. The use of pharmacological agents has shown some promise in the treatment of chronic venous disease. 3 Perhaps the most studied drug has been Daflon w (micronized purified flavonoid fraction) and clinical benefits have been demonstrated in a number of trials. 4 However, trials have been small and heterogeneous, and despite the popularity of Daflon w in parts of Europe, it is not available in many countries including the UK.
Deep venous surgery has been proposed by a number of centres, but the invasive nature of operations, often elderly patient population and limited effectiveness have restricted the widespread use of such interventions. Patients with occlusive deep venous disease may benefit from venous bypass procedures such as the Palma or May-Husni procedures. Venous stenting for deep venous occlusion has also been proposed, but is only performed in a few centres in significant numbers. 5 However, complete occlusion is present in only a minority of patients with deep venous disease, with valvular incompetence responsible for the majority. Internal and external valvuloplasty, venous transposition, vein valve autotransplantation and neovalve procedures have all been performed in an attempt to achieve lasting correction of deep venous incompetence and symptom relief. 6 However, long-term success has not been reliably demonstrated for any of these procedures, the morbidity of deep venous surgery is high and lifelong anticoagulation is usually required to reduce the risk of thrombosis. Consequently, deep venous surgery is only performed in a small number of centres worldwide and likely to be an available treatment option for only a small minority of patients.
Previous attempts to develop a percutaneous prosthetic vein valve implant have been disappointing. 7 Difficulties with early thrombosis led to most researchers abandoning their efforts many years ago. However, with the astonishing development of stem cell technology and modern stent designs and delivery systems, perhaps attempts to create a valve implant should be revisited. Although there are significant differences in arterial and venous vessels and flow, the expanding use of transfemoral or transapical aortic valve implants does highlight the potential of such technology.
Further efforts are clearly needed to improve outcomes for patients with deep venous disease. We need to improve our understanding of the relative significance of deep venous disease in individual patients. This information is essential in order to chose which patients may benefit from treatment to correct deep venous obstruction or reflux. New enthusiasm is needed to realize the potential of modern materials and technologies to develop novel minimally invasive treatment options for this forgotten patient group. Only then can the social, financial and personal impact of deep venous disease be addressed. 
H M Moore, M S Gohel and A H Davies

